Samsrita Labs Ltd
₹ 19.2
0.00%
22 Nov
- close price
About
Incorporated in 1996, Samsarita Labs Ltd is
in the business of healthcare services including hospital, diagnostics, Pharma, and Biotechnology (R&D)
Key Points
- Market Cap ₹ 28.5 Cr.
- Current Price ₹ 19.2
- High / Low ₹ 32.4 / 13.0
- Stock P/E
- Book Value ₹ 8.28
- Dividend Yield 0.00 %
- ROCE -1.72 %
- ROE -2.10 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 1.39% over last 3 years.
- Promoter holding has decreased over last 3 years: -5.40%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|
| 1.28 | 0.58 | 1.90 | 1.43 | 0.01 | 0.02 | 0.02 | 0.00 | |
| 1.86 | 1.71 | 4.34 | 3.62 | 0.92 | 0.43 | 1.01 | 0.25 | |
| Operating Profit | -0.58 | -1.13 | -2.44 | -2.19 | -0.91 | -0.41 | -0.99 | -0.25 |
| OPM % | -45.31% | -194.83% | -128.42% | -153.15% | -9,100.00% | -2,050.00% | -4,950.00% | |
| 0.01 | 0.03 | 0.11 | 0.16 | 0.15 | 1.91 | 0.29 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 |
| Profit before tax | -0.58 | -1.11 | -2.36 | -2.06 | -0.77 | 1.49 | -0.70 | -0.25 |
| Tax % | 124.14% | -5.41% | -1.27% | -3.40% | 0.00% | 0.00% | 0.00% | 0.00% |
| -1.31 | -1.05 | -2.33 | -1.98 | -0.77 | 1.49 | -0.71 | -0.26 | |
| EPS in Rs | -1.28 | -0.89 | -1.69 | -1.34 | -0.52 | 1.01 | -0.48 | -0.18 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -100% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 18% |
| TTM: | 63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -21% |
| 3 Years: | -10% |
| 1 Year: | 20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -4% |
| 3 Years: | 1% |
| Last Year: | -2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.26 | 11.76 | 13.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 |
| Reserves | -2.39 | -1.93 | -2.11 | -3.03 | -3.66 | -1.58 | -2.29 | -2.55 |
| 6.50 | 6.81 | 7.92 | 8.58 | 2.34 | 2.74 | 2.08 | 2.20 | |
| 4.88 | 6.26 | 6.61 | 7.85 | 3.09 | 1.16 | 0.96 | 1.09 | |
| Total Liabilities | 19.25 | 22.90 | 26.23 | 28.21 | 16.58 | 17.13 | 15.56 | 15.55 |
| 0.46 | 0.36 | 0.26 | 0.13 | 0.02 | 0.01 | 0.01 | 0.01 | |
| CWIP | 14.85 | 16.13 | 17.77 | 18.99 | 3.26 | 3.26 | 3.26 | 3.26 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 4.22 | 4.80 | 4.80 | 4.79 |
| 3.93 | 6.40 | 8.19 | 9.08 | 9.08 | 9.06 | 7.49 | 7.49 | |
| Total Assets | 19.25 | 22.90 | 26.23 | 28.21 | 16.58 | 17.13 | 15.56 | 15.55 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|
| -0.26 | -3.32 | -2.96 | -1.05 | -0.34 | -0.40 | 0.66 | -0.13 | |
| -1.09 | -1.19 | -1.55 | -1.11 | -0.23 | 0.00 | 0.00 | 0.00 | |
| 1.27 | 4.83 | 4.19 | 2.17 | 0.55 | 0.40 | -0.67 | 0.13 | |
| Net Cash Flow | -0.08 | 0.32 | -0.32 | 0.01 | -0.02 | 0.01 | 0.00 | 0.00 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 932.46 | 1,806.12 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | |
| Inventory Days | 0.00 | 0.00 | 0.00 | |||||
| Days Payable | ||||||||
| Cash Conversion Cycle | 932.46 | 1,806.12 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | |
| Working Capital Days | 738.55 | 2,026.38 | 733.84 | 727.45 | 146,000.00 | 108,770.00 | 84,132.50 | |
| ROCE % | -5.65% | -10.57% | -8.53% | -4.07% | 10.12% | -4.58% | -1.72% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Nov - Publication of un-audited financials of the company for the quarter ended on 30-09-2024 in the news papers
-
Un-Audited Financial Results For The Quarter Ended On 30-09-2024
11 Nov - Approval of unaudited financial results for Q2 2024.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 11-11-2024
11 Nov - Board approved unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Unaudited Results For The Quarter And Half Year Ended 30.09.2024
2 Nov - Board meeting scheduled for financial results on 11.11.2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
24 Oct - Certificate under Regulation 74(5) for no securities.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Products & Services:[1][2]
a) Stem Cell R&D:
Stem Cell Research & Therapy,
Regenerative Medicine, Bio-artificial
organ scaffolds development, nano-biotechnology, Nano-formulation of
cancer Drugs, Molecular genetics,
and Molecular virology, Stem cell
and Cord blood banking
b) New Drug Discovery:
Wilson’s disease, Non-Alcoholic Steatohepatitis (NASH), Neuropathic Pain, Cardiovascular Diseases, Cystinosis, Huntington’s disease
c) RNA Interference:
For developing a new panel of miRNAs
as a novel Bio Marker
d) Medical Devices:
Extra-corporeal liver support devices, Bioengineering implantable humanized nerve conduits, implantable nanochips carrying insulin-producing cells, extra-corporeal devices, etc.
e) Molecular Diagnostics:
DNA, RNA, and chromosomal based tests
and Pre-natal and pre-implantation genetic diagnostics, etc.
f) Contract Research Organization:
Synthetic Chemistry, Medicinal Chemistry, Drug Development, API’s process research, scale-up activity, Natural products research, and Analytical services